(via NewsDirect)
“One of the reasons we're so interested in having this broad clinical service footprint, is so we can undertake innovative treatments like MDMA assisted therapy,” Winlo said.
“We've got a trial that's we kicked that off last quarter and we've already started dosing with our first patients and that hopefully sets us up to turn this into a clinical service that we can offer to far more patients once we have the authorised prescriber program off and racing as well.
“We have also made good progress as far as drug development is concerned.”
Contact Details
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source